MannKind Corp

  • A Pharmacology Primer for the Biotech Investor

    By Seth Robey - August 16, 2013 | Tickers: LLY, MNKD, NVO, RHHBY

    In Pharmacology we don't only have to consider the actions of the drug on the body.  It is also important to understand the way the body processes the drug, or the Pharmacokinetics.  When you consider that drugs, like the nutrients in food, must be absorbed (A), distributed (D) throughout the body, metabolized (M), and excreted/eliminated (E), pharmacokinetics becomes a critical consideration in drug development.  Investors with a keen more »

  • A Closer Look at 3 Players in Diabetes Treatments

    By Leo Sun - August 16, 2013 | Tickers: MNKD, NVO, OSIR

    Two niche players in diabetes treatments -- Osiris Therapeutics (NASDAQ: OSIR) and MannKind (NASDAQ: MNKD) -- rallied strongly recently, after the two companies announced positive study results regarding their flagship products. Osiris, which uses stem cell treatments for bone and skin grafts, and MannKind, which is the last major company dedicated to producing inhalable insulin, are closely watched by biotech investors since an FDA approval would grant both companies instant monopolies in more »

  • Does New Data Make This Biotech a Good Buy?

    By Sherrie Stone - August 15, 2013 | Tickers: AMRN, MNKD

    Apparently, the third time's a charm for MannKind’s (NASDAQ: MNKD) Afrezza, an inhaled insulin device that has been rejected by the FDA on two other occasions. MannKind accepted guidance from the FDA, recently completed two Phase 3 trials for Type 1 and 2 diabetes, and now will likely earn a marketing approval. On Wednesday, the stock traded higher by nearly 11% after this news, making its gains 230 more »

  • An All-In Bet on a Game-Changing Diabetes Treatment

    By Leo Sun - August 14, 2013 | Tickers: JNJ, MNKD, MRK, PFE

    Note: This article has been amended to correct the spelling of Afrezza. Motley Fool apologizes for the error.

    In the biotech industry, there are generally two kinds of companies -- those that have established top and bottom line growth from approved products, and those that have pipelines of experimental treatments with a high potential for growth. Conservative investors favor the former, which include well-known companies like Pfizer (NYSE: PFE), Merck (NYSE: MRKmore »)

  • 2 Biotech Approval Outcomes That Might Affect You

    By Sherrie Stone - June 19, 2013 | Tickers: ARNA, MNKD, OREX, VVUS

    An FDA approval is the Holy Grail for biotechnology companies and their investors – but a successful launch is the most momentous in producing long-term gains. Thus, I am looking at two companies, both of which I expect to produce FDA approvals, but just one drug to create success in the open market.

    Possible approval, but not commercially successful

    MannKind Corporation (NASDAQ: MNKD) saw gains of more than 220% in 2013 more »

  • 2 Biotechs to Avoid, 1 to Buy

    By Mohsin Saeed - May 23, 2013 | Tickers: MNKD, OPTR, PDLI

    Keeping a close eye on two particular classes of investors can tell you a lot about how stocks might move in the future. Institutional investors have resources at their disposal that ordinary investors lack. Moreover, they own such large stakes in their investments that their moves can materially influence a stock's price.

    Meanwhile, important information about upcoming catalysts is more readily available to the insiders, compared to the rest more »

  • 3 Drug Catalysts to Watch in 2013

    By Brandy Betz - May 9, 2013 | Tickers: MNKD, MRK, PFE, RIGL, SNY

    Pharmaceutical investors: start your engines! We’re into the second quarter of 2013 and some major catalysts lurk right around the corner.

    Merck (NYSE: MRK) has a Food and Drug Administration meeting for a potential first-in-class insomnia treatment. The drug offers a better safety profile than the currently available treatments. MannKind (NASDAQ: MNKD)  returns with additional trial data that has delayed its anticipated diabetes inhalant. And Rigel Pharmaceuticals (NASDAQ: RIGLmore »)

  • Did This Stock Deserve This Sudden Upward Swing?

    By Jeremiah Feliciano - May 8, 2013 | Tickers: MNKD, NVS, VRTX

    Vertex Pharmaceuticals (NASDAQ: VRTX) shares surged from $52.87 on April 18 to a 12-year high of $85.90 per share on April 19 after the company reported positive outcomes from the Phase II clinical trial of its experimental drug, VX-661. Last time the stock witnessed such as rapid growth was on November 3, 2000, when the prices reached $93.87 a share.

    It’s only Phase II

    The drug more »

  • Three Outside the Box Biotechs

    By Streetwise Reports - April 1, 2013 | Tickers: BDX, LGND, MNKD, ONXX, UNIS

    By George S. Mack of The Life Sciences Report

    I had a really nice chat with Griffin Securities analyst and scientific director Keith Markey about a wide-ranging group of topics. My goal is to always talk about individual biotech and sometimes medtech stocks, but we got started on another subject right away. Although he’s been an analyst for 25 years now, Markey started his career as a molecular biologist more »

  • 3 Bio-Techs Insiders Love

    By Mohsin Saeed - March 19, 2013 | Tickers: INFI, MNKD, SQNM

    The biotechnology industry has given exceptional returns in the last couple of years. Quite a few stocks have soared due to FDA approval of their respective drugs. The high number of expiring patents has also forced larger bio-pharmaceutical companies to adopt aggressive acquisition strategies.

    The following three companies have seen strong insider buying during the last six months. This can be an indication of positive catalysts approaching because insiders have more »

  • 3 Bio-Pharmaceuticals Insiders Love

    By Mohsin Saeed - February 28, 2013 | Tickers: MNKD, MACK, TSRO

    Insiders are privy to information that is not available to other investors interested in a stock. Considering the fact that our stock picks and the overall stock market is driven by information, this information edge can make all the difference. This is the very reason there is an entire investment strategy on following insider trades. Following these trades gives investors an edge over others who are totally dependent on publicly more »

  • 100% Upside on these Bio-techs

    By Mohsin Saeed - January 31, 2013 | Tickers: GALE, MNKD, TEVA

    The approval of a drug candidate is one of the most important events for any biopharmaceutical company, and the approval event becomes even more important for biopharmaceuticals with a limited pipeline. This is because the valuations of the company are strongly affected by the approval or rejection of its candidate. The following two companies have major candidates nearing the end of Phase III clinical trials, and these drugs can significantly more »

  • A Biopharmaceutical Lottery Ticket

    By Mohsin Saeed - January 25, 2013 | Tickers: LLY, MNKD, PFE

    The recent failure of Pfizer (NYSE: PFE) in selling its inhalable insulin Exubera is forcing investors to seriously discount the commercial potential of inhalable insulin. It was the primary reason that major players such as Eli Lilly (NYSE: LLY) abandoned their own inhalable insulin products.

    The bad market sentiment about inhalable insulin has seriously affected the valuations of MannKind (NASDAQ: MNKD). This is the only reason it is trading at more »

  • Biopharma Stocks: Companies That Develops Studies For Type 2 Diabetes

    By Jorge Aura - December 11, 2012 | Tickers: AZN, BMS, JNJ, MNKD

    According to the World Health Organization (WHO), it is estimated that 346 million people around the world suffer from diabetes. Only in U.S. 26 million people suffer this illness.  Analysts reported that this market could jump from $35 billion to $50 billion by 2016. This situation provides an attractive market for large pharmaceutical and small biotech companies that want to look for a gap in the sector.

    Currently, the more »

  • Buy or Hold This Biopharmaceutical

    By Krishna Maheshwari - August 15, 2012 | Tickers: LLY, MNKD, NKTR, NVO, PFE

    Mannkind (NASDAQ: MNKD) is an inhalable drug company developing a fast acting, inhalable insulin (branded Afrezza) that is superior to any other insulin in the market today and a likely blockbuster drug.  They have completed phase III clinical trials and received no drug efficacy related pushback from the FDA, but have received two CRLs recently.  They are currently conducting two clinical trials to prove that the inhaler they intend to more »

  • The Good, the Bad, and the Ugly

    By Alexander Pavone - July 2, 2012 | Tickers: AAPL, CSCO, MNKD, SIRI

    Over on my old trading desk at RBC Capital Markets, we used to play a little stock picking game based off the Sergio Leone title starring Clint Eastwood. The goal of course was to choose 3 stocks, one good, one bad and one ugly and evaluate the action in each over the coming months. The idea was simply that the good should keep getting better, the bad should continue to more »

  • Bull Case for Mannkind

    By Krishna Maheshwari - May 24, 2012 | Tickers: ALKS, LLY, MNKD, NVO, PFE

    Mannkind (NASDAQ: MNKD) is a multi-bagger from its current levels in the next 1-3 years.

    This article will dive into the key elements of the investment thesis behind why I think Mannkind has such an enomous potential and will also highlight some of the risks.  As a summary, we have a serial entrepreneur with multiple successes in the CEO.  The drug has gone through Phase III clinical trials with no more »

  • Can These Biotechs Make You Money In 2012?

    By Robert Fisher - January 14, 2012 | Tickers: ARIA, DNDN, HGSI, ILMN, MNKD

    The biotech group is among the largest in the market in terms of the number of companies. They trade with perhaps the highest volatility in the market and move heavily on optimism of future successful drugs. The five biotech stocks on my radar today are Dendreon Corp. (NASDAQ: DNDN), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Human Genome Sciences (NASDAQ: HGSI), Illumina Inc. (NASDAQ: ILMN) and MannKind Corp. (NASDAQ: MNKD). The outlook more »